Clinical Trial

A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma

Study acronym: SPARCC
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this research study is to evaluate how well and safely the study drugs sasanlimab, palbociclib, and axitinib work for treatment of participants with advanced clear cell renal cell carcinoma (ccRCC) or translocation renal cell carcinoma (tRCC). The name of the study drugs involved in this research study is: * Sasanlimab (a type of monoclonal antibody) * Palbociclib (a type of kinase inhibitor) * Axitinib (a type of Vascular endothelial growth factor inhibitor)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-08; most recent amendment 2026-03-23.
Status change: Not Yet Recruiting → Recruiting 2026-03-23
Trial Details
NCT Number NCT07123090
Lead Sponsor Stephanie Berg
Collaborators: Pfizer
Conditions Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer, Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Kidney Cancer, Translocation Renal Cell Carcinoma
Enrollment 25 participants
Start Date 2025-11-24
Primary Completion 2026-10-01 (estimated)
Study Completion 2028-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-25